CME: Acute Myeloid Leukemia (AML): Therapeutic Updates, Best Practices, and Emerging Therapies
ACCREDITATION EXPIRED: April 28, 2016
Activity Description / Statement of Need:
In this online CME self-learning program:
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from the leukemias in the United States. It is estimated that about 14,590 people will be diagnosed with the disease in 2013 and will lead to approximately 10,370 deaths. The incidence of AML increases with age; the median age of diagnosis is 66 years. AML is also seen in children, although to a lesser extent than adults, and it appears to have a higher incidence in the Hispanic population. While the incidence of AML has been stable for the past two decades, treatment options have been continuing to advance and guidelines for therapy have been consistently updating to dramatically improve the outlook of patients with AML. Outcomes for 5-year survival in children under 15 years of age are between 45-55% but prognosis of adult care is worse than that of childhood leukemia. Taking all ages into account, the 5-year survival rate varies ranges from 20 and 30%.
Several classes of new drugs are being investigated as an alternative treatment approaches for refractory AML, including ubiquitin-proteasome pathway inhibitors, new novel nucleoside analogs, hypomethylating agents, histone deacetylase inhibitors, and angiogenesis modulators provide a hopeful future for successful AML therapy for refractory patients. Frequent updates to present treatment guidelines, representing an implicit practice gap, along with the burgeoning number of viable, biochemical targets in AML warrant continuing education programming aimed at the specialist that encompass current and potential future treatment options for patients with AML. This program has been designed to bring healthcare professionals’ knowledge of current and emerging treatment strategies for AML up to date and to improve their competence and performance in treating it.
Agenda
|
Epidemiology of and risk factors for AML |
|
Symptomology and diagnosis of AML |
|
Updates in treatment in patients with AML |
Target Audience:
Healthcare professionals specializing in: hematology, oncology, and those who otherwise commonly care for patients with AML.
Commercial Support Disclosure: This program is supported by educational grants from Boehringer-Ingelheim.
Release Date: April 28, 2014 -- Expiration Date: April 28, 2016
Faculty: Jonathan Kolitz, MD
Agenda
Learning Objectives
By the end of the session the participant will be able to:
- 1. Recognize factors affecting the diagnosis, staging, and prognosis of patients with AML.
- 2. Incorporate AML treatment strategies based on the most up to date clinical trial findings and clinical practice guidelines for AML.
- 3. Describe the risk-benefit calculus of AML management strategies and apply them to patient cases taking into account the latest information from and about evidence-based medicine, disease stage, prior treatment, past medical history, and prognostic indicators.
- 4. Evaluate a treatment plan for a specific patient based on degree of AML to optimize safety and efficacy, suggesting modifications for improvement.
- 5. Describe emerging therapeutic options for treating patients with AML.
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Jonathan Kolitz, MD is a stockholder in Celgene and Amgen, and is consultant for Ariad, Novartis, Sanofi, and Abbott.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from Boehringer-Ingelheim.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.